Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients by Ruberti, S et al.
OPEN
ORIGINAL ARTICLE
Involvement of MAF/SPP1 axis in the development of bone
marrow fibrosis in PMF patients
S Ruberti1,10, E Bianchi1,10, P Guglielmelli2, S Rontauroli1, G Barbieri1, L Tavernari1, T Fanelli2, R Norfo1,3, V Pennucci1, G Corbizi Fattori2,4,
C Mannarelli2,4, N Bartalucci2, B Mora5, L Elli5, MA Avanzini6, C Rossi1, S Salmoiraghi7, R Zini1, S Salati1, Z Prudente1, V Rosti8,
F Passamonti5, A Rambaldi7, S Ferrari9, E Tagliafico9, AM Vannucchi2,11, R Manfredini1,11on behalf of the AGIMM (AIRC Gruppo Italiano
Malattie Mieloproliferative) Investigators
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by hyperplastic megakaryopoiesis and myelofibrosis.
We recently described the upregulation of MAF (v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog) in PMF CD34+
hematopoietic progenitor cells (HPCs) compared to healthy donor. Here we demonstrated that MAF is also upregulated in PMF
compared with the essential thrombocytemia (ET) and polycytemia vera (PV) HPCs. MAF overexpression and knockdown
experiments shed some light into the role of MAF in PMF pathogenesis, by demonstrating that MAF favors the megakaryocyte and
monocyte/macrophage commitment of HPCs and leads to the increased expression of proinflammatory and profibrotic mediators.
Among them, we focused our further studies on SPP1 and LGALS3. We assessed SPP1 and LGALS3 protein levels in 115 PMF, 47 ET
and 24 PV patients plasma samples and we found that SPP1 plasma levels are significantly higher in PMF compared with ET and PV
patients. Furthermore, in vitro assays demonstrated that SPP1 promotes fibroblasts and mesenchymal stromal cells proliferation
and collagen production. Strikingly, clinical correlation analyses uncovered that higher SPP1 plasma levels in PMF patients correlate
with a more severe fibrosis degree and a shorter overall survival. Collectively our data unveil that MAF overexpression contributes
to PMF pathogenesis by driving the deranged production of the profibrotic mediator SPP1.
Leukemia (2018) 32, 438–449; doi:10.1038/leu.2017.220
INTRODUCTION
Primary myelofibrosis (PMF) is a Philadelphia-negative (Ph− )
myeloproliferative neoplasm (MPN). Ph− MPNs include poly-
cythemia vera (PV) and essential thrombocytemia (ET) besides
PMF and share a myeloproliferative phenotype with clonal
hematopoietic stem/progenitor cells expansion. On the basis of
the WHO classification of Ph− MPNs, the primary criteria for
differential diagnosis of PMF from ET and PV are the presence of
hyperplastic and dysplastic megakaryocytes with maturation
defects and the bone marrow (BM) fibrosis, that results from
reticulin and/or collagen fibers deposition.1 The malignant
hematopoietic cells, mainly megakaryocytes and monocytes, are
endowed of a proinflammatory and profibrotic phenotype in PMF
patients.2 The altered interplay between these cells and the BM
stromal cells in turn drives the development of myelofibrosis,
osteosclerosis and extramedullary hematopoiesis, that are all
features of PMF pathogenesis.3
Great efforts to unravel the genomic landscape of MPNs have
provided an increasing knowledge of the genomic lesions
responsible for the uncontrolled clonal proliferation, with the
identification of ‘driver’ mutations (JAK2, MPL and CALR) that
directly or indirectly lead to a deranged JAK/STAT signaling.4–7
Nevertheless, none of the genomic lesions described to date is
able to completely recapitulate all the pathological features of
PMF in vivo. Therefore, further efforts should be focused on
elucidating the molecular mechanisms behind the skewed cross-
talk between the malignant hematopoietic cells and BM micro-
environment to develop novel therapeutic options to dampen the
proinflammatory and profibrotic phenotype of malignant hema-
topoietic cells in PMF patients.2
To shed light on the molecular mechanisms underlying PMF
pathogenesis, we recently compared the gene expression profiles
of CD34+ hematopoietic progenitor cells (HPCs) from PMF
patients and healthy donors (HDs).8 This study provided many
insights into the molecular mechanisms potentially relevant for
PMF pathogenesis; notably we found the strong upregulation of
the transcription factor MAF (v-maf avian musculoaponeurotic
fibrosarcoma oncogene homolog) in CD34+ HPCs from PMF
patients.8
MAF belongs to the large-Maf family of transcription factors that
act as homo- or heterodimers by binding to the Maf-responsive
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elements.9,10 c-Maf gene gives rise to two splicing isoforms, MAF
variant 1 (RefSeq NM_005360.3) and MAF variant 2 (RefSeq
NM_001031804.1). The proteins encoded differ for their carboxy-
terminal portion. Translocations involving c-Maf locus are present
in 5% of multiple myeloma patients, whereas an additional 50% of
cases overexpresses MAF through an unknown mechanism.11 In
both these conditions, the oncogenic activity of MAF is linked to
its overexpression.
As MAF is upregulated in PMF HPCs compared with both the
HD-derived and the ET/PV patients-derived counterparts, here we
investigated the role of MAF in PMF pathogenesis.
Collectively, our data unveil that the upregulation of MAF in
PMF patients drives the expression of proinflammatory and
profibrotic genes in the HPCs progeny, therefore contributing to




Human CD34+ cells were purified upon donor’s informed written consent
from umbilical cord blood (CB) samples, collected after normal deliveries,
according to the institutional guidelines for discarded material. Monocytes
of HDs and PMF patients, and PMF CD34+ cells were purified from
peripheral blood (PB) samples. Plasma samples were collected from 186
patients with MPNs (115 PMF, 24 PV and 47 ET) and 60 HDs. BM
mesenchymal stromal cells (MSC) were collected from 5 HDs and 5 PMF
patients. All subjects provided informed written consent, and the study
was performed under the AGIMM (AIRC-Gruppo Italiano Malattie
Mieloproliferative) protocol (Comitato Etico Area Vasta dell'Azienda
Ospedaliero-Universitaria Careggi, approval date: 22 April, 2011, approval
file number # 2011/0014777).
MAF expression analysis in PMF and HD CD34+ cells
The raw Affymetrix data previously published8 for CD34+ cells isolated
from PMF patients (n=38) and HDs (n= 30; n= 14 from BM and n= 16 from
PB) were downloaded from the GEO repository (Series GSE85190). PMF
patients were further characterized by the JAK2, MPL or CALR mutation
carried and the BM fibrosis degree (Supplementary Table S1). The raw
Affymetrix data for CD34+ cells from PV (n= 24) and ET patients (n= 27; RZ
and RM, manuscript submitted) were also included for MAF expression
analysis.
The probe level data were normalized and converted into expression
values by using the robust multiarray average procedure in Partek GS. 6.6
Software Package (http://www.partek.com).
The comparative analyses of MAF expression in CD34+ cells from MPN
patients and HDs were performed by using the Kruskal–Wallis H-test when
comparing more than two independent groups. Next, the differences
between sample pairs were assessed by the Mann–Whitney U test.
Statistical analysis
The statistics used for in vitro experiments data analysis were based on
two-tailed Student’s t-tests for averages comparison in paired samples.
Data were analyzed by using Microsoft Excel (Microsoft Office, 2008
release) and are reported as mean± standard error of the mean (s.e.m.).
Po0.05 was considered significant. Statistical analyses for clinical
correlation were performed using the IBM Statistical Package for Social
Sciences (SPSS) statistics v23. Comparisons between groups were
performed by using the Mann–Whitney U test, and the chosen level of
significance was Po0.05 with a two-tailed test. Correlation between two
variables were examined by simple regression analysis. Patients with
plasma levels of SPP1 and LGALS3 greater than the median value reported
in normal plasma were considered high level patients. The cumulative
probability of overall survival (OS) was estimated using the Kaplan–Meier
method. Differences in OS among the groups were compared by using a
log-rank test in univariate analysis.
RESULTS
MAF expression levels in CD34+ cells from MPN patients
Microarray data for human primary CD34+ HPCs from PMF
patients (n= 38 from PB; n= 20 JAK2-mutated, n= 3 MPL-mutated,
n= 9 CALR-mutated and n= 6 triple-negative) and HDs (n= 14
from BM and n= 16 from PB) were obtained from a data set that
we previously published.8 The MAF expression data in BM-derived
CD34+ cells from ET (n= 27) and PV (n= 24) patients were
collected from an unpublished data set (RZ and RM, manuscript
submitted).
As we previously reported,8 MAF was strongly upregulated in
PMF patients compared with HDs (fold change (FC) = 8.69,
P= 4.25 × 10− 12; Figure 1a). Both the MAF splicing variants,
namely MAF variant 1 (hereafter reported as MAFVAR1, RefSeq
NM_005360.3) and MAF variant 2 (MAFVAR2, RefSeq
NM_001031804.1), were upregulated in PMF versus HD CD34+
cells (Supplementary Results and Supplementary Figure S1). In
addition, MAF was remarkably upregulated in PMF CD34+ cells
compared with ET (FC = 2.61, P= 1.62 × 10− 5) and PV counterparts
(FC = 2.99, P= 1.07 × 10− 6; Figure 1a). On the contrary, no
significant correlation between the mutation carried (JAK2, MPL,
CALR) and the expression levels of MAF in PMF patients was found
(Figure 1b). Although the expression of MAF appeared to be
slightly lower in triple-negative compared with JAK2-, MPL- and
CALR-mutated PMF patients (Figure 1b), this difference was not
statistically significant (P= 0.093). Furthermore, the same analysis
restricted to the JAK2V617F-positive PMF and ET patients did not
highlight any correlation between the JAK2V617F allele burden
and the MAF expression levels. Indeed, CD34+ cells from PMF
patients with different allele burden displayed superimposable
MAF expression levels (P40.05). No differences were detected
between JAK2V617 homozygous and heterozygous PMF patients
(P= 0.3837). Overlapping MAF expression levels were similarly
detected in ET patients regardless of their JAK2V617F allele
burden (P40.05) (Figure 1c).
Effects of STAT5 activation on MAF expression
We asked whether the JAK/STAT signaling could underlie the
overexpression of MAF in MPNs. As detected by Western Blot
(Supplementary Figure S2A), MAF protein level resulted increased
in MPL-expressing Ba/F3 cells upon treatment with TPO and,
therefore, STAT5 activation. Conversely, the treatment of
JAK2V617F-expressing Ba/F3 cells with increasing doses of
ruxolitinib caused a reduction of STAT5 activation and MAF
expression level (Supplementary Figure S2B).
Interestingly, ruxolitinib treatment lead to a reduction of MAF
expression level in PMF CD34+ cells (Supplementary Figure S2C)
that was even more remarkable and dose-dependent in PMF
monocytes (Supplementary Figure S2D).
Overall, these data confirm the connection between the
enhanced JAK/STAT signaling and the overexpression of MAF
in MPNs.
Role of MAF in HPCs lineage commitment and differentiation
To understand whether MAF could be relevant for PMF
pathogenesis, we studied the effects of its overexpression on
the lineage commitment and differentiation of HD-derived CD34+
HPCs. Collectively, our data demonstrated that MAF overexpres-
sion enhanced the monocyte/macrophage and megakaryocyte
differentiation of HD HPCs (Supplementary Results, Supplemen-
tary Table S2 and Supplementary Figure S3). In line with
these observations, MAF knockdown in PMF HPCs restrained
their megakaryocyte and monocyte/macrophage differentiation
(Supplementary Results and Supplementary Figure S4).
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Gene expression profile of MAF-overexpressing cells
To gain insights into whether and how the upregulation of MAF
detected in HPCs from PMF patients (Figure 1) could be relevant
for PMF pathogenesis, in a set of three independent experiments
CB-derived CD34+ HPCs transduced with the LMAFVAR1IDN,
LMAFVAR2IDN and LXIDN retroviral vectors were profiled by
Affymetrix U219 Array (Supplementary Results; Supplementary
Figures S5 and S6A–C).
A list of 729 differentially expressed genes (DEGs) in both
LMAFVAR1IDN- and LMAFVAR2IDN-transduced samples compared
to the controls was identified (Supplementary Tables S3
and S4).
Microarray data unveiled that several genes known to promote
fibrosis (for example, ENPP2,12 and ADAM9,13 Supplementary
Figure S6A) and inflammation (for example, TNF, CCL2,14 and
CCL3,15 Supplementary Figure S6B) were remarkably upregulated
upon MAF overexpression. Noteworthy, many of them encoded
for secreted proteins (Supplementary Figure S6C).
Owing to their putative role in inflammation and fibrosis,
which are key mechanisms in PMF pathogenesis, a subset of
Figure 1. Expression levels of MAF in CD34+ cells from MPN patients. Expression levels of MAF in CD34+ cells from MPN patients and HDs.
Gene expression levels were measured by microarray analysis performed by Affymetrix platform as detailed in Norfo et al.8 (please, see the
‘Materials and Methods’ section). MAF expression levels are reported as Robust Multiarray Analysis (RMA)-normalized log2 signals, which were
obtained by using the Partek GS software. Boxes represent the interquartile range that contains 50% of the subjects, the horizontal line in the
box marks the median, and bars show the range of values. Data in a are representative of 38 PMF, 27 ET, 24 PV and 30 HD samples (14 from BM
and 16 from PB). Only PMF (n= 38) and HD (n= 30) samples are shown in b, where PMF samples are classified into JAK2-mutated (n= 20), MPL-
mutated (n= 3), CALR-mutated (n= 9) and triple-negative (n= 6), based on the mutational status. Only JAK2V617F-positive PMF (n= 20) and ET
(n= 16) samples are shown in c, where samples are classified based on the JAK2V617F allele burden. BM, bone marrow; ET, essential
thrombocythemia; MPN, myeloproliferative neoplasm; PMF, primary myelofibrosis; PV, polycythemia vera; HD, healthy donor; PB, peripheral
blood; n, number of samples.
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transcripts coding for inflammation and fibrosis mediators was
selected for the qRT-PCR validation (Supplementary Table S5).
TaqMan
qRT-PCR was performed in LMAFVAR1IDN-, LMAFVAR2IDN- and
LXIDN-transduced cells from an independent set of five
experiments and allowed us to validate the expression of 7
out of 8 genes (87.5%) (Supplementary Figures S6D and E).
Expression of IL-8, THBS1, CCL2, PLAUR, MMP9, LGALS3 and SPP1
in culture supernatants from MAF-overexpressing cells and in
plasma from MPN patients
The secreted proteins coded by the 7 qRT-PCR-validated genes
were therefore assessed by means of an enzyme-linked immuno-
sorbent assay (ELISA) (a) in the culture supernatants from
LMAFVAR1IDN-, LMAFVAR2IDN- and LXIDN-transduced cells,
Figure 2. Detection of a subset of secreted molecules in LMAFVAR1IDN-, LMAFVAR2IDN- and LXIDN-transduced cells and in PMF patients
plasma by ELISA. Protein levels of seven secreted molecules (IL-8, a; CCL2, b; PLAUR, c; MMP9, d; LGALS3, e; SPP1, f; THBS1, g) were measured
by ELISA in culture supernatants from LMAFVAR1IDN, LMAFVAR2IDN and LXIDN-transduced cells (subpanels i) and plasma from PMF patients
and HDs (subpanels ii). Protein levels are expressed as ng/ml. Protein levels in culture supernatants from LMAFVAR1IDN-, LMAFVAR2IDN- and
LXIDN-transduced cells (subpanels i) are reported as mean± standard error of the mean (s.e.m.). *Po0.05; **Po0.01 versus LXIDN. The results
come from three independent experiments. Plasma levels in PMF patients and HDs (subpanels ii) are shown as dot plots. Boxes represent the
interquartile range that contains 50% of the subjects, the horizontal line in the box marks the median, and the bars show the range of values.
Data are representative of 30 PMF and 10 HD samples. Comparisons between HDs and PMF patients were performed by using the Mann–
Whitney U test, and the chosen level of significance was Po0.05 with a two-tailed test. ELISA, enzyme-linked immunosorbent assay; HD,
healthy donor; PMF, primary myelofibrosis.
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collected at 3 days post-purification and (b) in plasma samples of
PMF patients (n= 30) and HDs (n= 10) (Supplementary Table S6).
As shown in Figure 2, subpanels i, all the proteins selected
displayed significantly higher expression levels in both the MAF-
overexpressing samples compared with the controls. In addition,
IL-8, CCL2, PLAUR, MMP9, LGALS3 and SPP1 displayed significantly
higher plasma levels in PMF patients than in HDs (Po0.05;
Figures 2a–f, subpanels ii), whereas no difference was detected for
THBS1 (Figure 2gii).
As the increase of SPP1 and LGALS3 in the plasma of PMF
patients had never been reported before, we further analyzed
SPP1 and LGALS3 plasma levels in 85 additional PMF patients and
60 HDs, together with 47 ET and 24 PV patients (Supplementary
Table S6). As shown in Figure 3a, even though increased also in ET
and PV patients versus HDs, SPP1 plasma levels were significantly
higher in PMF versus ET (P= 0.0139) and PV patients (P= 0.0453).
On the contrary, LGALS3 plasma levels were increased in all the
MPN patients versus HDs (Po0.00001), with no remarkable
differences among PMF, PV and ET (Figure 3b).
Assessment of the mechanistic relation between MAF and SPP1/
LGALS3 expression
To shed some light on the mechanistic connection between the
increased MAF expression and the overproduction of SPP1 and
LGALS3, we assessed by Luciferase reporter assay the ability of
MAF to transactivate SPP1 and LGALS3 expression. The proximal
promoter regions of SPP1 and LGALS3 genes were cloned
upstream of the Firefly Luciferase gene. Luciferase assay demon-
strated that MAF is able to transactivate SPP1 promoter, as
increasing doses of MAF-coding vector caused a dose-dependent
induction in the luciferase activity (Figure 4ai). Conversely, MAF
did not significantly affect LGALS3 promoter-driven luciferase
expression (Figure 4aii).
Overall, these data indicated that MAF is able to directly
transactivate the expression of SPP1, but not of LGALS3.
Next, we wondered which cell types could be responsible for
SPP1 and LGALS3 secretion. Our data strongly suggested that
monocytes and megakaryocytes mainly account for SPP1 and
LGALS3 production (Supplementary Results and Supplementary
Figures S7A and B). Indeed, SPP1 and LGALS3 expression levels
were downregulated upon MAF knockdown in monocytes,
whereas only SPP1 was significantly downregulated in megakar-
yocytes (Figures 4bi and ii). Noteworthy, SPP1 expression was
remarkably reduced upon MAF knockdown in PMF CD34+ cells
(Figure 4biii).
Overall, these data reveal that MAF is able to transactivate SPP1
expression in monocytes and megakaryocytes. Of note, the
downregulation of SPP1 was also observed in PMF-derived HPCs
and monocytes after ruxolitinib treatment (Supplementary Results
and Supplementary Figures S7C and D).
Effects of recombinant human SPP1 and LGALS3 on inflammation
To investigate the role of MAF-induced SPP1 and LGALS3 in
inflammation, the expression of proinflammatory mediators
(namely, IL-8, IL-6, IL-1β and TNF-α) in HDs-derived monocytes
treated with recombinant human (rh)SPP1 or rhLGALS3 was
analyzed. qRT-PCR data showed that both SPP1 and LGALS3
enhanced the expression of proinflammatory mediators in
monocytes (Figure 4c).
Effects of rhSPP1 and rhLGALS3 on human fibroblasts and MSCs
Owing to the key role of BM fibrosis in PMF pathogenesis, we next
moved to unravel the effects of SPP1 and LGALS3, whose
increased plasma levels in PMF patients had never been reported
before, on fibroblasts proliferation and collagen production.
First, we treated normal human dermal fibroblasts with either
rhSPP1 or rhLGALS3. A sample treated with rhTGF-β1 was
included as positive control.
The treatment with rhSPP1 or rhLGALS3 in culture promoted
fibroblasts growth, as demonstrated by the increased cell counts
(Po0.05; Figure 5a) and cell density (Supplementary Figure S8A) in
rhSPP1- and rhLGALS3-treated fibroblasts at 24 and 48 h of culture.
In addition, the increase in cell count detected upon treatment with
rhSPP1 or rhLGALS3 was reversed by the simultaneous treatment
with SPP1 (Figure 5bi) or LGALS3 (Figure 5bii) neutralizing antibody,
respectively.
At last, we tried to elucidate whether rhSPP1 and rhLGALS3
could stimulate the fibroblasts to express collagen type III
Figure 3. Detection of SPP1 and LGALS3 in the plasma of MPN patients by ELISA. Protein levels of SPP1 (a) and LGALS3 (b) were measured by
ELISA in plasma samples derived from PMF (n= 115), ET (n= 47) and PV (n= 24) patients and HDs (n= 60). Protein levels are expressed as
ng/ml. Boxes represent the interquartile range that contains 50% of the subjects, the horizontal line in the box marks the median, and the bars
show the range of values. Comparisons between two groups were performed by using the Mann–Whitney U test, and the chosen level of
significance was Po0.05 with a two-tailed test. ELISA, enzyme-linked immunosorbent assay; ET, essential thrombocythemia; HDs, healthy
donors; n, number of samples; PMF, primary myelofibrosis; PV, polycythemia vera.
Role of MAF in primary myelofibrosis
S Ruberti et al
442
Leukemia (2018) 438 – 449
Figure 4. Role of MAF in the regulation of SPP1 and LGALS3 expression. (a) MAFvar1 and MAFvar2-dependent transactivation of human SPP1
promoter-driven (i) and LGALS3 promoter-driven (ii) luciferase expression. The amounts (in ng) of co-transfected plasmids are reported.
Renilla-normalized Firefly luciferase levels (mean± s.e.m.; n= 5 for SPP1 promoter and n= 5 for LGALS3 promoter, respectively) are normalized
by setting as = 1 the pXP1-SPP1(−853/+22)/LXIDN empty vector-transfected and the pXP1-LGALS3(−1720/+35)/LXIDN empty vector-
transfected samples, respectively. Error bars represent s.e.m. *Po0.05 compared to pXP1-SPP1(−853/+22)/LXIDN empty vector-transfected (i)
or pXP1- pXP1-LGALS3(−1720/+35)/LXIDN empty vector-transfected (ii) samples, respectively. (b) Expression levels of MAFvar1, MAFvar2, SPP1
and LGALS3 upon MAF knockdown in HD-derived (i) megakaryocytes (n= 6) and (ii) monocytes (n= 6) as well as (iii) in PMF patients-derived
CD34+ cells (n= 5) were measured by qRT-PCR 24 h post-nucleofection. Expression levels are reported as mean RQ± s.e.m. respect to the
NegCTRsiRNA sample, set as calibrator. *Po0.05; **Po0.01; ***Po0.001 versus NegCTRsiRNA. (c) Expression levels of proinflammatory
cytokines IL-8, IL-6, TNF-α and IL-1β in HDs monocytes are measured by qRT-PCR after 24 h of culture in the presence or absence of rhSPP1 or
rhLGALS3 and are reported as RQ (mean± s.e.m.; n= 6) respect to the untreated control samples, set as calibrator. *Po0.05 versus untreated
control. IL-1β, interleukin-1β; IL-6, interleukin-6; IL-8, interleukin-8; n, number of experiments; rh, recombinant human; RQ, relative quantity;
s.e.m., standard error of the mean; TNF-α, tumor necrosis factor-alpha.
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(COL3A1) and collagen type I (COL1A1), the main components of
reticulin and collagen fibers, respectively. qRT-PCR data showed
that treatment with rhSPP1 and rhLGALS3 induced the expression
of COL1A1 (Figure 5c), but not of COL3A1 (data not shown).
Given the role of MSCs in BM remodeling, we also investigated
the effects of rhSPP1 and rhLGALS3 on HD (Supplementary
Figures S8B–D) and PMF BM MSCs (Figure 6). The treatment with
rhSPP1 and rhLGALS3 increased both HD (Supplementary
Figure S8B) and PMF MSCs proliferation (Figure 6a). This
effect was reverted by treatment with SPP1 (Supplementary
Figure S8Ci and Figure 6bi) or LGALS3 neutralizing antibodies
(Supplementary Figure S8Cii and Figure 6bii).
In addition, rhSPP1 and rhLGALS3 induced COL1A1 expression
in both HDs (Supplementary Figure S8D) and PMF MSCs
Figure 5. Effects of SPP1 and LGALS3 on normal human fibroblasts. Effects of rhSPP1 and rhLGALS3 on proliferation of NHDFs. NHDFs were
cultured in the absence or presence of 500 ng/ml rhSPP1, 1000 ng/ml rhLGAL3 or 5 ng/ml rhTGF-β1 (as positive control) for 24 and 48 h.
(a) Evaluation of cell growth by Trypan Blue exclusion assay after 24 and 48 h of treatment. Results are shown as number of cells, starting from
5000 cells per sample, as reported in ‘Materials and Methods’ section. Values are reported as mean± standard error of the mean (s.e.m.); n= 6.
*Po0.05 versus untreated control. (b) Effect of an anti-SPP1 (i) and anti-LGALS3 (ii) neutralizing antibody on SPP1-induced NHDFs cell growth.
NHDFs were treated with rhSPP1 (i) or rhLGALS3 (ii) in the absence or presence of anti-SPP1 neutralizing antibody (2.5 μg/ml, bi) or anti-
LGALS3 neutralizing antibody (10 μg/ml, bii) or an isotype-matched antibody for 24 h. Cell growth was evaluated by Trypan Blue exclusion
assay. For each sample the fold of increase in cell counts after 24 h of culture is shown as normalized to the number of cells plated (t0). Values
are reported as mean± s.e.m. (n= 6). (c) Expression levels of COL1A1, an extracellular matrix-related gene involved in fibrosis, measured by
qRT-PCR after 24 h of culture in the presence or absence of rhSPP1, rhLGALS3 or rhTGF-β1 and are reported as RQ (mean± s.e.m.; n= 3)
respect to the untreated control samples, set as calibrator. COL1A1, collagen type 1 alpha 1; NHDFs, normal human dermal fibroblasts;
n=number of experiments; rh, recombinant human.
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(Figure 6c), whereas no modulation of COL3A1 mRNA level was
observed (data not shown).
Collectively, these results suggest that SPP1 and LGALS3
could promote fibroblast and MSC growth and collagen I production
and therefore could be involved in BM fibrosis in PMF patients.
Noteworthy, we also unveiled that the production of SPP1 was
higher in PMF versus HD MSCs. Strikingly, the treatment with PMF
monocytes-conditioned medium strongly increased the SPP1
protein release by PMF MSCs (Supplementary Results and
Supplementary Figures S8E and F).
Correlations between MAF, SPP1 and LGALS3 expression and
clinical features of PMF patients
As our data collectively supported the idea of a profibrotic role for
MAF/SPP1 axis, we further analyzed the expression levels of MAF
in CD34+ cells from PMF patients according to their BM fibrosis
grade. Strikingly, we uncovered that MAF expression levels in
CD34+ cells were significantly higher in overt fibrotic (MF-2/MF-3)
compared with prefibrotic (MF-0/MF-1) PMF (Figure 7a).
We next unraveled the correlations between SPP1 and LGALS3
plasma levels and clinical features of PMF patients. We first
compared hematological, clinical and molecular characteristics of
PMF patients according to the SPP1/LGALS3 expression levels in
the plasma in comparison with HDs. SPP1 and LGALS3 plasma
levels were significantly greater in PMF patients than in HDs
(median = 70.3 ng/ml, range = 10.3–392.4 ng/ml in PMF patients
versus median = 42.2, range = 4.4–87.4 ng/ml in HDs for SPP1,
Po0.00001 and median = 8.8 ng/ml, range = 1.6–36.2 ng/ml in
PMF patients versus median 5.4 ng/ml, range = 1.5–12.8 ng/ml in
HDs for LGALS3, Po0.00001).
Figure 6. Effects of SPP1 and LGALS3 on PMF mesenchymal stromal cells. PMF-derived MSCs were cultured in the absence or presence of
500 ng/ml rhSPP1, 1000 ng/ml rhLGAL3 or 5 ng/ml rhTGF-β1 (used as positive control) for 48 h. (a) Cell proliferation was monitored by Trypan
Blue exclusion assay after 48 h of treatment. Results are shown as number of cells, starting from 1.6 × 104 cells per sample. Values are reported
as mean± standard error of the mean (s.e.m.). The results come from three independent experiments. *Po0.05; **Po0.01 versus
untreated control. (b) Effect of an anti-SPP1 (i) and anti-LGALS3 (ii) neutralizing antibody on MSCs cell proliferation. PMF MSCs were treated
with rhSPP1 (i) or rhLGALS3 (ii) in the absence or presence of anti-SPP1 neutralizing antibody (2.5 μg/ml, bi) or anti-LGALS3 neutralizing
antibody (10 μg/ml, bii) or an isotype-matched antibody for 48 h. Cell proliferation was evaluated by Trypan Blue exclusion assay. For each
sample the fold of increase in cell counts after 48 h of culture was normalized to the number of cells plated at t0. Values are reported as
mean± s.e.m. (n= 5). *Po0.05. (c) Expression levels of the fibrotic marker COL1A1 in PMF MSCs were measured by qRT-PCR after 48 h of
culture with rhSPP1, rhLGALS3 or rhTGF-β1 and are reported as RQ (mean± s.e.m.; n= 5) respect to the untreated control sample, set as
calibrator. *Po0.05; **Po0.01. COL1A1, collagen type 1 alpha 1; MSCs, mesenchymal stromal cells; rh, recombinant human; n, number of
experiments.
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On the basis of SPP1 and LGALS3 plasma levels in HDs, we
defined high SPP1 (n= 88 patients), low SPP1 (n= 27), high
LGALS3 (n= 96) and low LGALS3 (n= 19) levels those patients
with SPP1/LGALS3 levels higher or lower, respectively, than the
median value in HDs (42.2 ng/ml for SPP1 and 5.4 ng/ml for
LGALS3).
Patients with higher SPP1 plasma levels suffered more
frequently of constitutional symptoms (94.9%) compared with
patients with normal SPP1 levels (67.1%; P= 0.001).
Further clinical correlations results are available in the
Supplementary Results section. The levels of SPP1 were progres-
sively higher depending on fibrosis grade, increasing from
fibrosis grade 0–1 (MF-0/1) (median = 51.8 ng/ml, range =
12.1–220.5 ng/ml, n= 54) to grade 2 (MF-2) (median = 96.0 ng/ml,
range= 10.3–392.4 ng/ml, n= 43) and grade 3 (MF-3)
(median= 103.5 ng/ml, range = 18.6–365.9 ng/ml, n= 18)
(P= 0.0016 in MF-2 versus MF-0/1 and P= 0.0021 in MF-3 versus
MF-0/1, Figure 7b). Furthermore, higher plasma levels of SPP1
were more frequently detected in the high molecular risk (HMR)
category (median = 113.8 ng/ml, range = 22.2–392.4 ng/ml) in
comparison with the low molecular risk group (median
57.2 = ng/ml, range = 10.3–364.7 ng/ml) (P= 0.014); no difference
was observed for LGALS3 levels according to HMR status. We then
evaluated the impact of SSP1 and LGAL3 plasma level on OS. In
univariate analysis, patients with higher SPP1 plasma levels
displayed significantly shorter OS compared to those with SSP1
level in the normal range (HR: 31, 95% CI: 1.0–183.7, P= 0.006;
Figure 7c) together with the IPSS variables evaluated at the time of
plasma collection (Po0.001). In multivariable Cox proportional
hazard regression analysis, higher SPP1 plasma levels remained
Figure 7. Clinical features of PMF patients according to MAF expression levels in CD34+ cells and SPP1 plasma levels. (a) MAF expression levels
in CD34+ cells isolated from PMF patients at diagnosis according to the BM fibrosis stage they presented. Patients were divided in prefibrotic
(MF-0/1, n= 7) and overt fibrotic (MF-2, n= 9 and MF-3, n= 14) based on the BM fibrosis grading. Gene expression levels were measured by
microarray analysis performed by Affymetrix platform as described in Norfo et al.8 MAF expression levels are reported as Robust Multiarray
Analysis (RMA)-normalized log2 signals, which were obtained by using the Partek GS software. Boxes represent the interquartile range that
contains 50% of the subjects, the horizontal line in the box marks the median, and bars show the range of values. The comparison between
MF-0/1 and MF-2/3 groups was performed by using the Mann–Whitney U test. (b) Protein levels of SPP1 in the plasma of PMF patients
(n= 115) according to BM fibrosis grade. PMF patients were classified based on grade of fibrosis in prefibrotic (MF-0/1, n= 54) and overt
fibrotic (MF-2, n= 43 and MF-3, n= 18). Protein levels were measured by ELISA and are expressed as ng/ml. Plasma levels of SPP1 are shown as
dot plots. Boxes represent the interquartile range that contains 50% of the subjects, the horizontal line in the box marks the median, and the
bars show the range of values. Comparisons between two groups were performed by using the Mann–Whitney U test. (c) Kaplan–Meier
estimates of overall survival in 115 patients with PMF, stratified by the plasma levels of SPP1. Patients with SPP1 plasma levels greater than the
median value observed in the plasma of HDs were considered patients with high SPP1 levels. BM, bone marrow; ELISA, enzyme-linked
immunosorbent assay; HDs, healthy donors; MF, myelofibrosis; PMF, primary myelofibrosis; n, number of samples.
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significant for survival (HR: 12.7, 95% CI:1.36–119.2; P = 0.026)
together with all the IPSS categories (HR: 3.7, 95% CI: 2.36–5.72;
Po0.0001), therefore representing an independent prognostically
adverse variable for survival in PMF.
DISCUSSION
As we have recently unveiled the upregulation of MAF in CD34+
cells from PMF patients compared with their normal
counterparts,8 in this study we further unraveled the role of
MAF in PMF pathogenesis.
We uncovered that MAF is also remarkably upregulated in PMF
CD34+ cells in comparison with ET and PV CD34+ cells. Notably,
MAF expression levels in CD34+ cells from PMF patients
are independent of the driver mutation they carry. We demon-
strated that MAF promotes the HPCs commitment toward the
monocyte/macrophage and megakaryocyte lineages, in line with
previous reports.16,17 Of note, both megakaryocytes and mono-
cytes are key players in PMF pathogenesis.18–21 Gene expression
profile of MAF-overexpressing cells provided further insights
into the role of MAF in PMF pathogenesis, as they unveiled
the enhanced expression of genes related to inflammation and
fibrosis.
PMF, as well as ET and PV, is associated with a chronic
nonresolving inflammation.22 This long-lasting inflammatory state
is fueled by the continuous release of proinflammatory and
microenvironment-regulating cytokines and chemokines, which
are mainly produced by megakaryocytes, monocytes and other
hematopoietic cells.23 Notably, elevated levels of circulating IL-8,
IL2R, IL12 and IL15 have been introduced as independent
prognostic criteria for PMF risk stratification according to the
Dynamic International Prognostic Scoring System (DIPSS plus).24
Similarly, increased plasma levels of proinflammatory cytokines
and chemokines, such as TNFα, IL-6 and CCL4, have been detected
in PMF patients and their reduction has been related to the clinical
benefits (that is, the resolution of splenomegaly and constitutional
symptoms) of ruxolitinib treatment.23,25
Our study unveils that the upregulation of MAF in CD34+ cells
from PMF patients is at least in part responsible for the induction
of a proinflammatory state and for the increased expression of
proinflammatory mediators in their progeny. Some of these
molecules (for example, IL-8, CCL2, PLAUR, SPP1 and LGALS3)
showed higher plasma levels in PMF patients compared to HDs.
Although CCL2,26 IL-824 and PLAUR27 have been already reported
to be increased in PMF patients in comparison with HDs, no data
were available for SPP1 and LGALS3,28,29 respectively. However,
both these molecules have been associated with other inflamma-
tory disorders. The upregulation of SPP1 is a hallmark of
inflammatory neuropathologies such as multiple sclerosis,30
Parkinson’s and Alzheimer’s disease.31 Similarly, LGALS3
promotes inflammation by stimulating macrophage activation
and migration and LGALS3 levels are associated with neutrophils
accumulation in patients with chronic obstructive pulmonary
disease.32
As SPP1 and LGALS3 increased plasma levels in PMF patients
had never been reported before, we further unraveled their role in
PMF-related inflammation by demonstrating that SPP1 and
LGALS3 enhance the expression of proinflammatory mediators
(namely, IL-8, IL-6, IL-1β and TNF-α) in monocytes.
No correlation between SPP1/LGALS3 plasma levels and
LDH levels, neutrophil or monocyte counts was found in PMF
patients, suggesting that the increased SPP1/LGALS3 plasma
levels did not exclusively reflect the ongoing chronic inflammation
in PMF.
Interestingly, even though several data demonstrate that MPN-
associated oncogenes can induce a proinflammatory response by
both malignant and non-malignant cells, emerging evidence
suggests that chronic inflammation itself may foster clonal
evolution in MPNs33,34 by increasing the risk of oxidative DNA
damage and consequently promoting the emergence of novel
genomic lesions. Therefore, the question of whether the MPN-
associated genomic lesions boost inflammation or vice versa still
remains unanswered.22 As JAK/STAT signaling is involved in both
malignant hematopoiesis and inflammation, we cannot exclude
that chronic inflammation in the BM rather than JAK/MPL/CALR-
driven oncogenic signaling could underlie the upregulation of
MAF in CD34+ cells. However, our data demonstrate that MAF
contributes to enhance the proinflammatory microenvironment
that is a major feature of PMF and, to a lesser extent, of the
other MPNs.
Concerning the development of BM fibrosis and stromal
changes characterizing PMF,18–21 the most acknowledged theory
is that they result from an overproduction of growth factors by
malignant hematopoietic cells, mainly monocytes and megakar-
yocytes. The proinflammatory/profibrotic cytokines and
growth factors released (for example, TGFbeta, PDGF, bFGF and
VEGF) in turn act on stromal cells leading to the development of
BM fibrosis, osteosclerosis and other pathological features of
PMF.18–21
Here we demonstrate that the upregulation of MAF in
malignant HPCs from PMF patients contributes to enhance the
expression of several profibrotic mediators, such as CCL2,35 IL-8,36
MMP9,37 LGALS3 and SPP1 in their progeny. Indeed, all the latter
molecules show significantly increased plasma levels in PMF
patients in comparison with HDs. We showed that SPP1 is a direct
transcriptional target of MAF, whereas the mechanism of LGALS3
overproduction upon MAF overexpression still remains unclear.
Interestingly, both LGALS3 and SPP1 have been previously linked
to the development of liver fibrosis.38,39 In line with these data, we
demonstrated that SPP1 promotes fibroblasts and MSCs prolifera-
tion and collagen production. In addition, in line with the
increasing evidences suggesting that stromal cells may foster
key pathophysiological features of PMF,3 we showed that the
production of SPP1 is significantly higher in PMF MSCs compared
with their normal counterparts and, interestingly, their crosstalk
with PMF monocytes strongly enhances the SPP1 production
by MSCs.
Our study showed that SPP1 plasma levels in PMF patients have
a prognostic value as they were able to distinguish prefibrotic
(MF-0/MF-1) and overt fibrotic (MF-2/MF-3) PMF patients.40,41
Indeed, higher SPP1 plasma levels correlate with a more severe
fibrosis degree in PMF patients. Strikingly, we also uncovered a
significant correlation between the higher SPP1 plasma levels and
a shorter OS in PMF patients.
As a whole, in this study we demonstrate that the upregulation
of MAF in malignant CD34+ cells is a key mechanism for the
induction of a proinflammatory and profibrotic phenotype in their
differentiated progeny (Supplementary Figure S9). Both JAK2, MPL
and CALR mutations converge toward the STAT5 activation,4,42,43
and, consequently, the STAT5-driven transactivation of MAF
expression.44 Indeed, JAK inhibition by ruxolitinib treatment
reduced MAF expression in PMF HPCs and monocytes.
Nonetheless, the upregulation of MAF is also detected in triple-
negative PMF patients; moreover, JAK2-mutated PMF patients
with different allele burden- and therefore different STAT5
activation- display superimposable MAF expression levels. In
addition, MAF expression is further enhanced in PMF versus ET
and PV CD34+ cells, in spite of the same driver mutations.
Therefore, we speculate that other molecular mechanisms should
be involved in the control of MAF expression in PMF.
In the present study, we showed for the first time an increased
expression of LGALS3 and SPP1 in MPN patients’ plasma
compared to HD; however, while LGALS3 could be considered a
putative serum marker of MPN, SPP1 increased expression is more
remarkable in PMF patients, in which it is related to a greater
degree of BM fibrosis and shorter OS.
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As a whole, in the present study we demonstrated that MAF–
SPP1 axis is involved in the development of BM fibrosis with
potential prognostic value in PMF patients.
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